At the news
? BULLISHIMPACT 8/10 6-K filed Sep 14, 2026 at 16:52 ET
Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer). This is a transformative regulatory milestone that opens a new commercial product line in a large, underserved U.S. market (~24,000 new glioma cases/year) and reinforces Telix's leadership in theranostics. The approval is a clear, material positive catalyst for the stock.
- FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent/progressive glioma from treatment-related change in adults and pediatric patients 1 month+
- Pixclara is the first and only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
- Approximately 24,000 new glioma cases are diagnosed annually in the U.S., representing a significant addressable market
- FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access